Pharm-a-Care/ Haliborange merger inquiry
The CMA has investigated and cleared the anticipated acquisition by Pharm-a-Care Laboratories Pty Limited of the Haliborange Business of the Procter and Gamble Company
Statutory timetable
| Date | Action |
|---|---|
| 13 July 2020 | Decision published |
| 23 June 2020 | Decision announced |
| 11 May 2020 | Launch of merger inquiry |
| 5 to 19 May 2020 | Invitation to comment |
Phase 1
Clearance decision
23 June 2020: The CMA has cleared the anticipated acquisition by Pharm-a-Care Laboratories Pty Limited of the Haliborange business of the Procter & Gamble Company.
- (13.7.20)
Launch of merger Inquiry
11 May 2020: The CMA announced the launch of its merger inquiry by notice to the parties.
- (11.5.20)
Invitation to comment: closes 19 May 2020
5 May 2020: The Competition and Markets Authority (CMA) is considering whether it is or may be the case that this transaction, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation may be expected to result in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.
To assist it with this assessment, the CMA invites comments on the transaction from any interested party.
These comments should be provided by the deadline set out above.
Contact
Please send written representations about any competition issues to general.enquiries@cma.gov.uk.
Updates to this page
Last updated 13 July 2020 + show all updates
-
Full text of the clearance decision published.
-
Clearance decision announced.
-
Launch of the merger inquiry and commencement notice published.
-
First published.